AU2001231192A1 - Mob-5/hmob-5 as a cancer diagnostic marker - Google Patents

Mob-5/hmob-5 as a cancer diagnostic marker

Info

Publication number
AU2001231192A1
AU2001231192A1 AU2001231192A AU3119201A AU2001231192A1 AU 2001231192 A1 AU2001231192 A1 AU 2001231192A1 AU 2001231192 A AU2001231192 A AU 2001231192A AU 3119201 A AU3119201 A AU 3119201A AU 2001231192 A1 AU2001231192 A1 AU 2001231192A1
Authority
AU
Australia
Prior art keywords
hmob
mob
diagnostic marker
cancer diagnostic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231192A
Other languages
English (en)
Inventor
Peng Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2001231192A1 publication Critical patent/AU2001231192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2001231192A 2000-01-26 2001-01-26 Mob-5/hmob-5 as a cancer diagnostic marker Abandoned AU2001231192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17818500P 2000-01-26 2000-01-26
US60/178,185 2000-01-26
PCT/US2001/002680 WO2001055170A1 (fr) 2000-01-26 2001-01-26 Mob-5/hmob-5 utilise comme marqueur diagnostic pour le cancer

Publications (1)

Publication Number Publication Date
AU2001231192A1 true AU2001231192A1 (en) 2001-08-07

Family

ID=22651551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231192A Abandoned AU2001231192A1 (en) 2000-01-26 2001-01-26 Mob-5/hmob-5 as a cancer diagnostic marker

Country Status (3)

Country Link
EP (1) EP1254155A4 (fr)
AU (1) AU2001231192A1 (fr)
WO (1) WO2001055170A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767656A3 (fr) * 2001-10-30 2007-07-25 Ortho-Clinical Diagnostics, Inc. Procedes pour estimer et traiter la leucemie
US20040110792A1 (en) * 2001-10-30 2004-06-10 Mitch Raponi Methods for assessing and treating leukemia
WO2003082255A2 (fr) * 2002-04-03 2003-10-09 Novartis Ag Utilisation de mob-5 pour combattre la douleur
WO2005060998A2 (fr) * 2003-12-03 2005-07-07 Schering Corporation Methodes de modulation de l'activite de la cytokine et reactifs connexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695540B2 (en) * 1993-10-27 1998-08-13 Trustees Of Columbia University In The City Of New York, The Method for generating a subtracted cDNA library and uses of the generated library
US6262333B1 (en) * 1998-06-10 2001-07-17 Bayer Corporation Human genes and gene expression products

Also Published As

Publication number Publication date
WO2001055170A1 (fr) 2001-08-02
EP1254155A4 (fr) 2003-06-18
EP1254155A1 (fr) 2002-11-06
WO2001055170A9 (fr) 2002-10-17

Similar Documents

Publication Publication Date Title
AU2002224520A1 (en) A cannula
AU2001233626A1 (en) Marker
AU2001280796A1 (en) Electrowetting-driven micropumping
AU3889500A (en) Radiographic reference marker
AU2001252599A1 (en) Remedies for cancer
AU2001280598A1 (en) Anti-occlusion catheter
AU2002360377A1 (en) Baalc expression as a diagnostic marker for acute leukemia
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2002239403A1 (en) Tissue specific prodrugs
AU4826500A (en) A marker assembly
AU2001270082A1 (en) Gene markers for lung cancer
AU2000263864A1 (en) Tissue specific prodrug
AU2001282149A1 (en) Improved marker
AU2001242342A1 (en) Antiperspirants
AU2001231192A1 (en) Mob-5/hmob-5 as a cancer diagnostic marker
GB0216884D0 (en) Diagnostic marker
AU2001279630A1 (en) Tumor activated prodrug compounds
AU2001295815A1 (en) Multiple purpose catheter
AU2000238755A1 (en) Dermatological compounds
AU2001268744A1 (en) Characterizing a brain tumor
AU4437001A (en) Bend stiffener
AU2001278829A1 (en) Nitrogen-potassium fertiliser
AU6759601A (en) Well
AU2001291842A1 (en) A catheter
AUPQ901800A0 (en) Line marker